Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

RecruitingOBSERVATIONAL
Enrollment

1,002

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Type 2 DiabetesCardiovascular Complication
Trial Locations (1)

60127

RECRUITING

IRCCS INRCA Hospital, Ancona

All Listed Sponsors
lead

Istituto Nazionale di Ricovero e Cura per Anziani

OTHER